BullFrog AI Holdings a precision medicine company using artificial intelligence and machine learning to enable the successful development of pharmaceuticals and biologics,announced the appointment of Enrique García-Rivera, Ph.D., as its new Vice President of Artificial Intelligence. The appointment will further advance BullFrog AI’s best-in-class proprietary bfLEAP AI platform that is engineered to enable more accurate predictions of patient disease progression and improve the design .
“We are excited to welcome Enrique to BullFrog AI. His exceptional track record in AI and biomedical research, coupled with his unique ability to translate complex data into meaningful insights, will further bolster the capability of our bfLEAP AI platform to glean insights from incomplete data sets, perform multimodal analysis and reveal valuable patterns and relationships across deep and wide nodes of unstructured data,” commented Vin Singh, CEO of BullFrog AI. “I am confident that his expertise will drive our bfLEAP AI platform to new heights and strengthen our position at the forefront of AI-driven ultimately paving the way for more effective and personalized therapeutic solutions.”
Prior to joining BullFrog AI, Dr. García-Rivera held leadership roles at ROME Therapeutics and nference in Cambridge, MA. At ROME Therapeutics, he led clinical applications and platform engineering, and while at nference, he developed a drug discovery platform and led various research efforts. Previously Dr. García-Rivera was a research associate at the Broad Institute of Harvard and MIT, where he identified a novel kinase dependency in synovial sarcomas through large-scale small molecule profiling. His vast experience in developing machine learning models and managing large biological databases further augments BullFrog AI’s industry-leading capabilities.
“In a few short years, BullFrog AI has demonstrated the potential of its bfLEAP AI platform to identify new drug targets and predict patient outcomes, accelerating drug development and enabling optimized clinical trial design,” stated Dr. García-Rivera. “I look forward to joining such a talented team dedicated to pushing the boundaries and fulfilling the promise of artificial intelligence in pharmaceutical research and development.”
